CN1981762A - Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method - Google Patents
Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method Download PDFInfo
- Publication number
- CN1981762A CN1981762A CN 200510132127 CN200510132127A CN1981762A CN 1981762 A CN1981762 A CN 1981762A CN 200510132127 CN200510132127 CN 200510132127 CN 200510132127 A CN200510132127 A CN 200510132127A CN 1981762 A CN1981762 A CN 1981762A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- anisodine
- procaine
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composite medicine for treating pneumonia, pulmonary fibrosis, cerebral infarction, cardiovascular and cerebrovascular ischemic diseases, ischemic eye disease, etc is prepared from anisodine (0.05-0.4 Wt portions) and procaine (5-40). Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, related in particular to a kind of pharmaceutical composition for the treatment of pneumonia, cardiovascular and cerebrovascular disease and preparation method thereof, belonged to the Western medicine field.
Background technology
Anisodine hydrobromide is a kind of new alkaloids of China's invention, acts on autonomic nervous system, is M cholinergic nerve blocker, has spasmolytic, mydriasis, suppresses salivation, the microcirculation improvement effect.Because the common dose side effect is big, reduce to the untoward reaction that minimum dosage still has headache, poor sleep, so clinically abandon.
Procaine (PR), another name, novocain (Novocaine).The capable local infiltration anesthesia of procaine commonly used clinically, nerve block anesthesia have functions such as the autonomic nerve of adjustment and cerebral cortex.
Up to now, still do not have report in the prior art, can effectively treat pneumonia, pulmonary fibrosis, diseases such as cardiovascular and cerebrovascular vessel ischemic pathological changes by Anisodine and the composite pharmaceutical composition of procaine.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, provides a kind of and can effectively treat pneumonia, pulmonary fibrosis, the pharmaceutical composition of cardiovascular and cerebrovascular vessel ischemic pathological changes.
Technical problem to be solved by this invention realizes by following technological approaches:
A kind ofly can effectively treat pneumonia, pulmonary fibrosis, the pharmaceutical composition of cardiovascular and cerebrovascular vessel ischemic pathological changes, form by the component of following weight portion:
Anisodine 0.05-0.4 part and procaine 5-40 part.
In order to reach better therapeutic effect, the weight portion of each component is preferably Anisodine 0.05-0.2 part, procaine 5-20 part; Or Anisodine 0.1-0.4 part, procaine 10-40 part.
Preferred: the weight portion of each component is 0.1 part of Anisodine, 10 parts of procaines;
Pharmaceutical composition of the present invention can be adjusted autonomic nerve, illness such as the internal organs of autonomic nerve regulation and control, blood vessel, body of gland is also all had exciting, promotes the Accommodation of autonomic nerve, thereby can treat the illness at these positions; Can make the choroidal artery active substance keep normal level, improve the vasomotion function, blood flow increasing is so have significant therapeutic effect to former and secondary eye ischemia; Pharmaceutical composition of the present invention can also reduce free radical, stablizes and the protection vascular endothelial cell, consolidates the permeability of blood vessel wall; Promote edema, ooze out, hemorrhage absorption, promote side to prop up circulation and set up, make histo pathological change light.Clinically, pharmaceutical composition of the present invention is effectively treated interstitial pneumonia and pulmonary fibrosis, cerebral infarction, myocardial infarction and coronary heart disease, myocardial ischemia angina pectoris and diseases such as paroxysmal tachycardia, ischemic eye disease.In addition, medicine of the present invention can also make hypertension reduce to normally, and hypotension rises to normally, and has the sleep of improvement, the effect of eliminate pain.
Usually the present composition is suitable for oral administration and drug administration by injection, also is fit to other medication.
The present composition can add various conventional adjuvant required when preparing different dosage form, as excipient, filler, disintegrating agent, wetting agent, diluent etc., make oral formulations commonly used (for example: capsule, tablet, powder, granule, lozenge, oral liquid etc.) or non-oral administration drug-delivery preparation forms such as injection, infusion solution or suppository with the formulation method of routine.。
Wherein, described conventional excipients is such as binding agent, for example syrup, arabic gum, gelatin, sorbitol, tragacanth or polyvinylpyrrolidone; Filler, for example lactose, sugar, corn starch, calcium phosphate, sorbitol or glycine; Tabletting lubricant, for example magnesium stearate; Disintegrating agent, for example starch, polyvinylpyrrolidone, Explotab or microcrystalline Cellulose; Or pharmaceutically acceptable wetting agent, such as sodium lauryl sulphate.
The pharmaceutical preparation of the present composition can prepare with conventional mixing, filling or pressed disc method.Repeating married operation can be used for activating agent fully is distributed to the compositions of using a large amount of filling doses.Conventional in such operation yes this area.Tablet can make coated tablet or plain sheet according to conventional preparation method.
The oral liquid of the present composition can be the form of example emulsion, syrup or elixir, perhaps can be used as dry products and exists, and water or other suitable carriers reconstitute again before the use.
In addition, also can pharmaceutical composition of the present invention be made sustained-release preparation, as slow-release micro-pill or controlled release micro pill according to conventional method.
The usage of pharmaceutical composition of the present invention and consumption: the dosage of medicine of the present invention depends on concrete dosage form, and factor such as age of patient, body weight, health status.As guidance: oral formulations, each oral 10-20ml that is grown up, every day 1-2 time, 10 times is a course of treatment.
The specific embodiment
Specify the present invention below with reference to embodiment, embodiments of the invention only are used to technical scheme of the present invention is described, and non-limiting essence of the present invention.
The preparation of [embodiment 1] injection
Anisodine 0.05mg
Procaine 5mg
Normal saline 20ml
Above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
The preparation of [embodiment 2] injection
Anisodine 0.2mg
Procaine 20mg
Normal saline 20ml
Above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
The preparation of [embodiment 3] injection
Anisodine 0.06mg
Procaine 6mg
Normal saline 6ml
Above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
The preparation of [embodiment 4] injection
Anisodine 0.15mg
Procaine 15mg
Normal saline 15ml
Above composition is mixed, and the preparation of the preparation method of injection promptly routinely.
The preparation of [embodiment 5] oral liquid
Anisodine 0.1mg
Procaine 10mg
Cold water 100ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The preparation of [embodiment 6] oral liquid
Anisodine 0.4mg
Procaine 40mg
Distilled water 200ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The preparation of [embodiment 7] oral liquid
Anisodine 0.2mg
Procaine 20mg
Distilled water 120ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The preparation of [embodiment 8] oral liquid
Anisodine 0.3mg
Procaine 30mg
Distilled water 150ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The preparation of [embodiment 9] oral liquid
Anisodine 0.25mg
Procaine 25mg
Distilled water 125ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The preparation of [embodiment 10] oral liquid
Anisodine 0.35mg
Procaine 35mg
Distilled water 155ml
Above composition is mixed, and the preparation of the preparation method of oral liquid promptly routinely.
The clinical observation on the therapeutic effect test of test example 1 medicine composite for curing interstitial pneumonia of the present invention and pulmonary fibrosis
Supply the reagent thing: the injection that the embodiment of the invention is prepared.
Therapeutic Method: intravenous injection, every day 1 time, 10 times is a course of treatment.
During SARS, the Li Yumin president of People's Armed Police hospital general, Tianjin, give 21 routine patients with interstitial pneumonia with for the treatment of reagent thing, make patient's chest pain, the sx of feeling oppressed, the patient respiratory frequency is reduced to 21-24 time by surplus 40 times, partial pressure of oxygen raises, X sheet demonstration lung interstitial lung inflammation is obviously improved, and absorbs rapidly, and the result shows, for the reagent thing can inflammation-inhibiting, ooze out, hemorrhage, hyperplasia and fibrosis, can effectively treat interstitial pneumonia and pulmonary fibrosis.
The 2 medicine composite for curing cerebral infarction clinical observation on the therapeutic effect tests of the present invention of test example
Supply the reagent thing: the injection that the embodiment of the invention is prepared.
Therapeutic Method: intravenous injection, every day 1 time, 10 times is a course of treatment.
A left side Basal ganglia small pieces cerebral infarction and lacunar infarction patient 12 examples, right skelasthenia is walked several steps and will be taken a momentary rest and just can continue, and for 2 of reagent things, slowly vein injects, and treats a course of treatment, and symptom disappears entirely.
Test example 3 medicine composite for curing myocardial infarctions of the present invention and the test of coronary heart disease clinical observation on the therapeutic effect
Supply the reagent thing: the injection that the embodiment of the invention is prepared.
Therapeutic Method: intravenous injection, every day 1 time, 10 times is a course of treatment.
Example surplus acute and old heart infarction patient and the patients with coronary heart disease 10, chest pain has constriction, and is nervous; tachycardia in the intravenous drip 50ml normal saline, adds for 2 of reagent things by tee T; slowly splash into, treatment back symptom rapidly disappears, and can improve myocardial ischemia.
The 4 medicine composite for curing ischemic eye disease clinical observation on the therapeutic effect tests of the present invention of test example
Supply the reagent thing: the oral liquid that the embodiment of the invention is prepared.
Therapeutic Method: oral medication, be grown up each 2 every day 1-2 time, each 1 of infant, 10 times is a course of treatment, treats 1-2 the course of treatment.
Treatment ischemic eye disease patient 30 examples, minimum birth of age 7 months, maximum 81 years old.Through 30 routine ischemic eye disease patient observed results are shown, pharmaceutical composition of the present invention reaches 97.8% to the total effective rate of 30 routine ischemic eye diseases treatments, illustrates that pharmaceutical composition of the present invention can effectively treat ischemic eye disease.
The influence of test example 5 pharmaceutical composition dialogue Cor Leporis myocardial ischemias of the present invention
With 30 of New Zealand white rabbit, make myocardial infarction and ischemia model, establish for reagent thing (oral liquid that the embodiment of the invention is prepared) treatment group, composite salvia dropping pill for curing group, normal saline matched group, 10 every group.The result: for the examination medication therapy groups, New Zealand white rabbit, the heart infarction postoperative is taken for behind the reagent thing, hair smoothing, postoperative recovered feed the same day, and appetite is good, and body weight does not subtract, and activity is freely after 3 days.Saline group and composite salvia dropping pill for curing group postoperative, hair is rough, sends out and kills, and appetite obviously lowers, and body weight obviously reduces.After the course of therapy, put to death, analyze the myocardial ischemia scope with computer image treatment, compare for examination medication therapy groups and composite salvia dropping pill for curing group, normal saline matched group, significantly improve for reagent thing group myocardial ischemia, remarkable significant difference is arranged, both zero differences of back.
Test example 6 medicine composite for curing myocardial ischemia of the present invention angina pectoriss and the test of paroxysmal tachycardia clinical observation on the therapeutic effect
Supply the reagent thing: the oral liquid that the embodiment of the invention is prepared.
Therapeutic Method: oral medication, be grown up each 2 every day 1-2 time, 10 times is a course of treatment, treats 1-2 the course of treatment.
Routine patient surplus treatment myocardial ischemia angina pectoris and the paroxysmal tachycardia 20,1-2 time/day, dosage: 2/time, send down with cold boiled water water.In 3 minutes-20 minutes, patient's symptom is obviously improved, angina, and tachycardia returns to normal level.Observed result shows that pharmaceutical composition of the present invention can effectively be treated myocardial ischemia angina pectoris and paroxysmal tachycardia.
Claims (9)
1. treat pneumonia, pulmonary fibrosis for one kind, the pharmaceutical composition of cardiovascular and cerebrovascular vessel ischemic pathological changes is made up of the component of following weight portion: Anisodine 0.05-0.4 part and procaine 5-40 part.
2. according to the pharmaceutical composition of claim 1, it is characterized in that the weight portion of described component is: Anisodine 0.05-0.2 part, procaine 5-20 part.
3. according to the pharmaceutical composition of claim 1, it is characterized in that the weight portion of described component is: Anisodine 0.1-0.4 part, procaine 10-40 part.
4. according to the pharmaceutical composition of claim 3, it is characterized in that the weight portion of described component is: 0.1 part of Anisodine, 10 parts of procaines.
5. according to the pharmaceutical composition of claim 1, it is characterized in that being prepared into oral formulations, injection, infusion solution or suppository according to the conventional formulation method.
6. according to the pharmaceutical composition of claim 5, it is characterized in that described preparation is oral liquid or injection.
7. claim 1 or 2 the pharmaceutical composition purposes in preparation treatment interstitial pneumonia and pulmonary fibrosis, cerebral infarction, myocardial infarction and medicaments for coronary disease.
8. claim 1 or 3 the pharmaceutical composition purposes in preparation treatment ischemic eye disease, cardiovascular and cerebrovascular vessel ischemic pathological changes medicine.
9. according to the purposes of claim 8, it is characterized in that described cardiovascular and cerebrovascular vessel ischemic pathological changes comprises myocardial ischemia angina pectoris or paroxysmal tachycardia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510132127 CN1981762A (en) | 2005-12-16 | 2005-12-16 | Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510132127 CN1981762A (en) | 2005-12-16 | 2005-12-16 | Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1981762A true CN1981762A (en) | 2007-06-20 |
Family
ID=38164794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510132127 Pending CN1981762A (en) | 2005-12-16 | 2005-12-16 | Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1981762A (en) |
-
2005
- 2005-12-16 CN CN 200510132127 patent/CN1981762A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW518222B (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
| CN101478961B (en) | S1P receptor modulators for treating multiple sclerosis | |
| CA2383785C (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| AU748993B2 (en) | Pharmaceutical combinations containing tramadol | |
| MX2012013014A (en) | Therapeutic regimens. | |
| JP5680412B2 (en) | Use of Leonurine and compositions thereof | |
| CN1142767A (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
| CN1674907A (en) | Use of reboxetine for the treatment of hot flashes | |
| Park et al. | Efficacy of D-CPPene, a competitive N-methyl-D-aspartate antagonist in focal cerebral ischemia in the rat | |
| Hood Jr | Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine | |
| EP0846465B1 (en) | Nicorandil against anxiety neurosis | |
| US4315033A (en) | Method of treating menopausal symptoms | |
| CN1981762A (en) | Medicinal composition for treating pneumonitis and cardiovascular diseases and its making method | |
| AU2010276461B2 (en) | Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta receptor blocking agent, and use thereof | |
| CN1768760A (en) | Medicinal composition containing safflower total flavone and its preparation process and usage | |
| CN100404039C (en) | Safflower medicine composition and its prepn process and use | |
| KR20030019444A (en) | New use of angiotensin ii antagonists | |
| CA2957949A1 (en) | Dexmecamylamine for use in the treatment of hyperhidrosis | |
| US8470363B2 (en) | Antihypertensive pharmaceutical composition | |
| JP3947582B2 (en) | Anxiety treatment | |
| CN107281183B (en) | Analgesic composition | |
| RU2506947C2 (en) | Prolonged release tablet containing theobromin | |
| RU2464984C2 (en) | Non-steroid anti-inflammatory drug | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| JPS59144717A (en) | Analgesic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |